AI-Powered Blood Tests Enable Early Detection of Alzheimer’s Disease
Posted on 10 Oct 2025
Alzheimer’s disease, the most common form of dementia, affects more than 55 million people globally. Early diagnosis is critical for managing symptoms and slowing progression, yet current testing methods rely on costly, complex lab procedures that are often unavailable in local clinics or developing countries. This limits timely detection and treatment for millions of patients. Researchers have now developed a simple, affordable blood test capable of identifying Alzheimer’s biomarkers at an early stage using handheld, artificial intelligence (AI)-assisted technology.
Scientists at the University of Liverpool (Liverpool, UK) have designed a portable diagnostic platform that combines molecularly imprinted polymer-based biosensors with AI to measure Alzheimer’s biomarkers in blood. The system operates through a compact reader and web-based app, requiring only a drop of blood for analysis. Unlike standard hospital tests, it eliminates the need for specialized equipment or training and provides near-instant results at a fraction of the cost.
Two studies demonstrate how simple handheld devices can provide affordable and early detection of Alzheimer’s disease. In the first study published in Advanced Healthcare Materials, the team created a biosensor that uses “plastic antibodies” attached to a porous gold surface to detect extremely low concentrations of phosphorylated tau 181 (p-tau181)—a protein strongly associated with Alzheimer’s disease. The sensor demonstrated high sensitivity and accuracy across different blood samples, producing results comparable to gold-standard laboratory methods.
In the second study, published in ACS Sensors, researchers have described an alternative sensor built on a printed circuit board, similar to those used in consumer electronics. Coated with a unique chemical layer, it detected the same biomarker and successfully differentiated between healthy individuals and Alzheimer’s patients. Despite its simplicity, the device performed nearly as well as expensive lab-based platforms like SIMOA, confirming its suitability for point-of-care diagnostics.
The portable system links to an AI-powered reader and cloud-based app, which instantly analyzes data and provides diagnostic insights. Because of its affordability and portability, the technology could enable decentralized Alzheimer’s screening in GP offices, community health centers, and rural clinics worldwide. It aligns with the World Health Organization’s call for accessible, low-cost diagnostic tools for brain diseases.
“Our goal is to make Alzheimer’s testing as accessible as checking blood pressure or blood sugar,” said corresponding author Dr. Sanjiv Sharma. “By combining low-cost sensors with affordable electronics and artificial intelligence, we can deliver accurate results for multiple biomarkers in minutes.”
Related Links:
University of Liverpool
